The invention encompasses novel compounds of Formula or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.
α-Carbonyl Radicals from <i>N</i>-Enoxybenzotriazoles: De Novo Synthesis of 9-Phenanthrols
作者:Quynh H. Nguyen、Tae-Woong Um、Seunghoon Shin
DOI:10.1021/acs.orglett.2c03356
日期:2022.11.18
donors or alcoholic solvents led to α-carbonylradicals. The utility of the α-carbonylradicals was demonstrated in intramolecular tandemcyclization and in the synthesis of 9-phenanthrols and their analogues. The mechanistic experiments suggested that quenching of the reactive benzotriazolyl radical by the alcohol was accompanied by the formation of an α-hydroxy radical that mediated hydrogen atom transfer
[EN] PHENANTHRENE DERIVATIVES AS MPGES-1 INHIBITORS<br/>[FR] DÉRIVÉS DE PHÉNANTHRÈNE EN TANT QU'INHIBITEURS DE MPGES-1
申请人:MERCK FROSST CANADA LTD
公开号:WO2007134434A1
公开(公告)日:2007-11-29
[EN] The invention encompasses novel compounds of Formula or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmacuetical compositions are also encompassed. [FR] L'invention concerne de nouveaux composés de formule ou des sels pharmaceutiquement acceptables de ceux-ci. Ces composés sont des inhibiteurs de l'enzyme prostaglandine E synthase-1 microsomale (mPGES-1) et sont par conséquent utiles pour traiter la douleur et/ou l'inflammation créées par une diversité de maladies ou d'états, telles que l'ostéo-arthrite, la polyarthrite rhumatoïde et la douleur aiguë ou chronique. L'invention concerne également des procédés de traitement de maladies ou d'états à médiation par l'enzyme mPGES-1 et des compositions pharmaceutiques.